First, quantitative laboratory testing of XTW and comparable pen needles was completed with the 3 insulin pens for thumb force, flow rate, and time to deliver medication. Followed by a prospective, randomized, 2-period, cross-over clinical trial with patients aged 35 to 80 years with DM, some with impaired hand dexterity, who injected insulin by pen for ≥2 months; with at least 1 daily dose ≥10 U. Patients who used 4-to 8-mm length pen needles with 31-to 32-G were randomly assigned to use their current pen needle or the same/similar size XTW pen needle at home for 1 week and the other PN the second week. They completed several comparative 150-mm visual analog scales and direct questions at the end of the last period.
Methods:
First, quantitative laboratory testing of XTW and comparable pen needles was completed with the 3 insulin pens for thumb force, flow rate, and time to deliver medication. Followed by a prospective, randomized, 2-period, cross-over clinical trial with patients aged 35 to 80 years with DM, some with impaired hand dexterity, who injected insulin by pen for ≥2 months; with at least 1 daily dose ≥10 U. Patients who used 4-to 8-mm length pen needles with 31-to 32-G were randomly assigned to use their current pen needle or the same/similar size XTW pen needle at home for 1 week and the other PN the second week. They completed several comparative 150-mm visual analog scales and direct questions at the end of the last period.
Results:
In laboratory testing, XTW pen needles had statistically significant better performance for thumb force, flow, and time to deliver medication for all pens combined and each individual pen brand, all p≤0.05. When the BD 4mm x 32G was compared to comparable pen needles, thumb force was reduced by 62%, flow rate increased by 149%, and time to deliver medication reduced by 60%. In the clinical study, 216 subjects were randomized (SoloSTAR, 80; FlexPen, 77; KwikPen, 59) , with 198 evaluable. Baseline characteristics were mean age of 60.8 years, insulin pen use duration of 4.3 years, and mean total daily dose of 75.1 units (range 10-420 units). Approximately 50% were female, 82% white, 14.8% black, and 90% type 2 DM. The 8mm pen needle was used by 49.5% and 12% used the 4mm length.
Compared to usual pen needles, the XTW pen needles were rated as being significantly more preferable (68%), requiring less thumb force (61%), less painful (64%), easier to insert (64%), providing greater confidence in full dose delivery (52%) and less time to inject dose (49%), all p<0.001.
Results were similar for each of the 3 pens, those with impaired hand dexterity, and for all users of 4-mm pen needles.
Skin leakage and insulin dripping from the needle tip were rated as significantly less frequent with the XTW pen needles (p<0.05). In addition, laboratory testing demonstrated there are no differences in bending or breakage between thin wall and the XTW pen needles.
Conclusions:
Compared to usual pen needle, extra thin-walled pen needles with improved insulin flow were preferred, rated as requiring less thumb force, less painful, easier to insert, provided greater confidence in giving a full dose and less time to deliver the dose.
